Biology-driven cancer drug development: back to the future

Por Lord, Christopher J, Ashworth, Alan
Publicado em 2010

NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells

Por Mendes-Pereira, Ana M., Lord, Christopher J., Ashworth, Alan
Publicado em 2012

An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence

Por Rovillain, Emilie, Mansfield, Louise, Lord, Christopher J, Ashworth, Alan, Jat, Parmjit S
Publicado em 2011

DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells

Por Gudmundsdottir, Katrin, Lord, Christopher J, Witt, Emily, Tutt, Andrew N J, Ashworth, Alan
Publicado em 2004

Structural basis for recruitment of BRCA2 by PALB2

Por Oliver, Antony W, Swift, Sally, Lord, Christopher J, Ashworth, Alan, Pearl, Laurence H
Publicado em 2009

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity

Por Frankum, Jessica, Moudry, Pavel, Brough, Rachel, Hodny, Zdenek, Ashworth, Alan, Bartek, Jiri, Lord, Christopher J.
Publicado no Oncotarget (2015)

APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer

Por Brough, Rachel, Bajrami, Ilirjana, Vatcheva, Radost, Natrajan, Rachael, Reis-Filho, Jorge S, Lord, Christopher J, Ashworth, Alan
Publicado em 2012

Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition

Por Sourisseau, Tony, Maniotis, Despina, McCarthy, Afshan, Tang, Chan, Lord, Christopher J, Ashworth, Alan, Linardopoulos, Spiros
Publicado em 2010

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

Por Bajrami, Ilirjana, Kigozi, Asha, Van Weverwijk, Antoinette, Brough, Rachel, Frankum, Jessica, Lord, Christopher J, Ashworth, Alan
Publicado em 2012

The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate Notch signalling

Por Rajan, Neil, Elliott, Richard J.R., Smith, Alice, Sinclair, Naomi, Swift, Sally, Lord, Christopher J., Ashworth, Alan
Publicado no Oncotarget (2014)

p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene

Por Arias-Lopez, Carmen, Lazaro-Trueba, Iciar, Kerr, Peter, Lord, Christopher J, Dexter, Tim, Iravani, Marjan, Ashworth, Alan, Silva, Augusto
Publicado em 2006

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2

Por Martin, Sarah A, McCarthy, Afshan, Barber, Louise J, Burgess, Darren J, Parry, Suzanne, Lord, Christopher J, Ashworth, Alan
Publicado em 2009

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

Por Turner, Nicholas C, Lord, Christopher J, Iorns, Elizabeth, Brough, Rachel, Swift, Sally, Elliott, Richard, Rayter, Sydonia, Tutt, Andrew N, Ashworth, Alan
Publicado em 2008

Dysregulated TRK Signalling is a Therapeutic Target in CYLD Defective Tumours

Por Rajan, Neil, Elliott, Richard, Clewes, Oliver, Mackay, Alan, Reis-Filho, Jorge S., Burn, John, Langtry, James, Sieber-Blum, Maya, Lord, Christopher J., Ashworth, Alan
Publicado em 2011

Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase

Por Mereniuk, Todd R., El Gendy, Mohamed A.M., Mendes-Pereira, Ana M., Lord, Christopher J., Ghosh, Sunita, Foley, Edan, Ashworth, Alan, Weinfeld, Michael
Publicado em 2013

Overexpression of MYB drives proliferation of CYLD‐defective cylindroma cells

Por Rajan, Neil, Andersson, Mattias K, Sinclair, Naomi, Fehr, André, Hodgson, Kirsty, Lord, Christopher J, Kazakov, Dmitry V, Vanecek, Tomas, Ashworth, Alan, Stenman, Göran
Publicado no J Pathol (2016)

DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1

Por Martin, Sarah A., McCabe, Nuala, Mullarkey, Michelle, Cummins, Robert, Burgess, Darren J., Nakabeppu, Yusaku, Oka, Sugako, Kay, Elaine, Lord, Christopher J., Ashworth, Alan
Publicado em 2010

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway

Por Conti, Annalisa, Majorini, Maria Teresa, Elliott, Richard, Ashworth, Alan, Lord, Christopher J., Cancelliere, Carlotta, Bardelli, Alberto, Seneci, Pierfausto, Walczak, Henning, Delia, Domenico, Lecis, Daniele
Publicado no Oncotarget (2015)

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Por Costa-Cabral, Sara, Brough, Rachel, Konde, Asha, Aarts, Marieke, Campbell, James, Marinari, Eliana, Riffell, Jenna, Bardelli, Alberto, Torrance, Christopher, Lord, Christopher J., Ashworth, Alan
Publicado no PLoS One (2016)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Por Costa-Cabral, Sara, Brough, Rachel, Konde, Asha, Aarts, Marieke, Campbell, James, Marinari, Eliana, Riffell, Jenna, Bardelli, Alberto, Torrance, Christopher, Lord, Christopher J., Ashworth, Alan
Publicado no PLoS One (2016)